Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy.
about
HCV Diversity among Chinese and Burmese IDUs in Dehong, Yunnan, ChinaThe Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in ChinaHCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeHCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infectionGenotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks.Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection.Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patientsGenotypes and subtypes of hepatitis C virus in Burundi: a particularity in sub-Saharan Africa.Hepatitis C genotype 4: genotypic diversity, epidemiological profile, and clinical relevance of subtypes in Saudi Arabia.New NS5B polymerase inhibitors for hepatitis C.Antiviral therapy: why does it fail in HCV-related chronic hepatitis?Interferon combination therapy for HIV/hepatitis C virus coinfection.Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal.A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.Subtype distribution of hepatitis C virus in Jiangsu, China.The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience.Hepatitis C virus genotyping using an oligonucleotide microarray based on the NS5B sequence.Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.Correlation of the 5'untranslated region (5'UTR) and non-structural 5B (NS5B) nucleotide sequences in hepatitis C virus subtyping.A clustering phenomenon among HCV-1a strains among patients coinfected with HIV from Buenos Aires, Argentina.Comparison of envelope 2 CD81 binding regions in PBMC-derived versus serum-derived hepatitis C virus isolates: higher conservation of CD81 region 2 in PBMC isolates.Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.Gel-based microarrays in clinical diagnostics in Russia.Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections: A real-life experience.Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy.
P2860
Q27468608-7A0EAFEA-E149-40D9-AD49-E7B18BB4F82CQ28550281-60B5342C-6D47-45BB-ADFA-4A23B5FE203AQ31012317-924CF071-350B-468D-9122-17C4A546F716Q34479825-B758335F-67C6-42E0-8FE9-C7F868603DE8Q34489239-9234A15E-25D0-428F-935C-8A34BF330B01Q34746864-177BC92B-3C2F-4676-A093-18B6F3526AC0Q34806845-A05B31F8-3C76-41DF-ABD7-99053B737D0FQ35037574-8868DA13-FD7C-4B6B-A890-0A4EEA0D60BAQ35077010-45FDDA42-CE10-4966-9750-1EEB5628B7C8Q35090280-8EF9F6DA-777D-45BE-A600-E89B85E10855Q36702487-077DAF7E-0D52-4C9F-BB08-F8F3EA9056BEQ37772518-6FE5671E-2466-4EE9-AAC2-0A54C41E3AFAQ37879193-A9516EB9-FA21-4199-8269-EF3ADCCC5BBFQ37931258-D53EFA41-A36D-4ACD-9DB4-3AAD24147DC9Q38929061-4735EEAC-F56C-4BB8-97C8-D5E8026EE86EQ39751806-EBAE4439-B639-4CC5-9332-E0777C14C95BQ40627310-E7FE30D6-FEB9-4CD6-98B5-EDC20C07C26BQ40694971-AA5BFC9A-191B-4045-8C0F-61ECD7450284Q41829739-2DCE5968-8889-4540-B378-ACD252E98584Q42242611-0FF5658F-8A71-4758-900E-3FF16FB9FD5AQ42716855-BB977201-5BED-471E-85B2-458E3F084C3EQ42977748-3AA34A91-FDC9-4C8E-BF78-4771CFF162F9Q42996047-6E3B7263-ACF5-4893-B2EA-993760AABA49Q43033729-B0EBBFB2-775A-4956-810F-6E369C328B5FQ43041150-B055D6CB-9A61-40AC-A6FC-77EFE0A7B62BQ43172450-DC63E558-4909-45D1-9002-393FB34573CCQ47564117-85526815-F1BE-4EAB-956B-1841E4ED8C88Q50554156-578F4837-FA97-4DCE-86D8-B6D246C43BC9
P2860
Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Influence of the HCV subtype o ...... erferon and ribavirin therapy.
@en
Influence of the HCV subtype o ...... erferon and ribavirin therapy.
@nl
type
label
Influence of the HCV subtype o ...... erferon and ribavirin therapy.
@en
Influence of the HCV subtype o ...... erferon and ribavirin therapy.
@nl
prefLabel
Influence of the HCV subtype o ...... erferon and ribavirin therapy.
@en
Influence of the HCV subtype o ...... erferon and ribavirin therapy.
@nl
P2093
P50
P356
P1476
Influence of the HCV subtype o ...... erferon and ribavirin therapy.
@en
P2093
Anne-Marie Roque-Afonso
Bruno Pozzetto
Bruno Roche
Catherine Gaudy
Christophe Hézode
Christopher Payan
Dominique Roulot
Evelyne Schvoerer
Florence Legrand-Abravanel
Françoise Lunel-Fabiani
P304
P356
10.1002/JMV.21583
P50
P577
2009-12-01T00:00:00Z